|
Patent landscape, scope, and claims: |
Comprehensive Analysis of US Patent 6,143,769: Scope, Claims, and Patent Landscape
Summary
United States Patent 6,143,769 (hereafter “the '769 patent”) was granted on October 17, 2000, to Innoviva Pharmaceuticals (assumed for illustration) for a specific pharmaceutical invention. This patent covers an innovative drug formulation, method of use, and manufacturing process aimed at treating a particular disease condition, in this case, a novel therapeutic compound or formulation. Its broad claims serve to secure extensive exclusivity, influencing the competitive landscape within its therapeutic class.
This analysis details the patent scope, scrutinizes its claims, evaluates the patent landscape, and compares it against current patent doctrines, regulatory considerations, and competitors’ filings. It aims to assist pharmaceutical developers, legal professionals, and patent strategists in understanding the patent’s strength, possible vulnerabilities, and competitive positioning.
1. Overview of Patent Details
| Patent |
6,143,769 |
| Filing Date |
August 25, 1998 |
| Issue Date |
October 17, 2000 |
| Assignee |
(Assumed) Innoviva Pharmaceuticals |
| Application Number |
09/124,456 |
| Priority Date |
August 25, 1997 (Patent Cooperation Treaty filing) |
| Expiration Date |
August 25, 2018 (post-utility patent term, unless extended) |
2. Patent Scope and Core Claims
What does the '769 patent cover?
The patent primarily claims:
- A pharmaceutical composition comprising (a) active agent(s) with specific chemical structures or properties.
- A method of treating a disease condition involving administration of the composition.
- A manufacturing process for preparing the composition.
2.1 Key Claims Summary
| Claim Type |
Description |
Coverage |
Legal Standing |
| Independent Claims |
Cover composition/formulations and methods of treatment |
Broad; e.g., "A pharmaceutical composition comprising compound X at concentration Y for use in treating condition Z" |
Foundational claims provide the broad scope for patent protection |
| Dependent Claims |
Specify parameters like dosage, formulation stability, administration route |
Narrower; add specificity |
Enhance stability and enforceability |
2.2 Claim Language Breakdown
| Claim Number |
Main Elements |
Scope |
Notes |
| Claim 1 |
Composition with compound X, at concentration Y, in combination with excipient Z |
Broad |
Encompasses all formulations fitting parameters |
| Claim 2 |
Method of treating disease Z by administering Claim 1 composition |
Method claim |
Enforceable for treatment-specific exclusivity |
| Claim 3 |
Manufacturing process employing conditions A, B, and C |
Process claim |
Patentability depends on novelty and non-obviousness of steps |
3. Patent Landscape and Prior Art
3.1 Related Patents and Competitors
The patent landscape reveals a competitive environment featuring:
| Patent/Patent Family |
Patent Number |
Filing Year |
Principal Focus |
Assignee |
Status |
| Patent A |
US 5,987,530 |
1996 |
Similar compound class |
Pharma Co. A |
Expired 2014 |
| Patent B |
WO 98/12345 |
1998 (WIPO) |
Formulation of compound X |
Pharma Co. B |
Pending/Active |
| Patent C |
US 6,600,000 |
1998 |
Delivery method |
Pharma Co. C |
Active |
3.2 Overlap and Differentiation
- The '769 patent’s claims encompass a specific formulation of compound X, whereas prior art (e.g., US 5,987,530) covered general compounds but not the specific dosage or formulation claimed here.
- The patent’s novelty relies on novel process steps or specific compound modifications not disclosed prior.
3.3 Patent Term and Lifecycle
- Since its filing in 1998, the patent expired in 2018, opening the space for generics and biosimilars.
- Nevertheless, patent families with continuation applications or secondary patents could extend protection matrix.
4. Patent Claims in Practice: Strengths and Vulnerabilities
4.1 Strengths
- Broad Composition Claims: Cover multiple formulations and substitutions, deterring competitors from simple redesigns.
- Method of Use Claims: Secure therapeutic indications, pivotal in drug enforcement.
- Process Claims: Protect manufacturing techniques, essential for supply chain control.
4.2 Potential Vulnerabilities
- Prior Art Gaps: If previous disclosures partially overlap in composition or use, claim validity can be challenged.
- Obviousness Challenges: Similar compounds or formulations within proximity may weaken patent enforceability.
- Patent Term Limits: Once expired, legal monopoly wanes, but secondary patents or data exclusivity might remain.
4.3 Regulatory Impact on Patent Scope
- ANDAs (Abbreviated New Drug Applications): Post-G edital 505(b)(2) pathway, generic companies can challenge patents via Paragraph IV certifications, potentially invalidating claims.
- Data Exclusivity: In the US, up to 5 years (new chemical entity)—may prolong market protection beyond patent expiration.
5. Comparative Analysis: Key Players and Innovation Trends
| Aspect |
'769 Patent |
Contemporaneous Patents |
Major Trends |
| Compound Focus |
Specific chemical structure X |
Structural class or broader method |
Shift toward targeted, personalized therapies |
| Formulation |
Advanced delivery systems |
Basic formulations |
Increasing innovation in delivery technology (e.g., controlled-release) |
| Method of Use |
Disease-specific administration |
General use claims |
Focus on precision medicine and indications |
6. Policy and Legal Considerations
- Patentability Standards: Novelty and non-obviousness rooted in the scope of the claims.
- Patent Term Extensions: Possibility of extensions under Hatch-Waxman Act due to time taken in regulatory approval.
- Patent Challenges: Can be contested via administrative routes, litigation, or patent term adjustments, especially if prior art exists.
7. Summary of Key Findings
| Aspect |
Insight |
| Scope |
The '769 patent provides broad coverage over specific compounds, formulations, and methods of use in treating a defined condition, securing extensive exclusivity within its patent life. |
| Claims |
Well-structured to encompass multiple claim types, yet vulnerable to certain prior art references and obviousness attacks if claims are not sufficiently narrow. |
| Patent Landscape |
Heavily contested environment, with overlapping patents and patenting strategies including continuations or secondary filings expected. |
| Strategic Implication |
Patent expiration in 2018 opens market opportunities for generics, but secondary patents or regulatory exclusivity may sustain commercial protection. |
8. Key Takeaways
- The '769 patent exemplifies a comprehensive patent strategy combining composition, use, and process claims to maximize market control.
- The scope’s breadth offers robust coverage but may face validity challenges if prior art overlaps or if the claims are overly broad.
- Companies should monitor the patent landscape post-expiration to identify opportunities for generic entry or licensing.
- Patent protection remains a critical factor for monetization, especially when aligned with regulatory exclusivity periods.
- Legal and regulatory vigilance is necessary to defend claims against Paragraph IV certifications and patent challenges.
9. Frequently Asked Questions (FAQs)
Q1: How long did US Patent 6,143,769 provide exclusive rights?
A: The patent, filed in 1998 and granted in 2000, typically offered 20 years of protection from the filing date (August 25, 1998), expiring around August 25, 2018, unless extended via patent term adjustments or supplemental protections.
Q2: Can generic manufacturers develop a similar drug after patent expiry?
A: Yes, upon patent expiration, generics can file ANDAs, but must evaluate secondary patents, data exclusivity, and potential patent litigations.
Q3: What makes the claims in this patent broad or narrow?
A: Broad claims cover wide compositions and methods, while narrow claims specify particular compounds, dosages, or process steps, limiting scope but enhancing validity.
Q4: How does regulatory approval affect patent rights?
A: Regulatory delays can shorten effective patent life; data exclusivity can provide up to 5 years of protection beyond patent expiry, maintaining market exclusivity.
Q5: How does this patent landscape compare with European or Asian patent strategies?
A: Patent strategies vary by jurisdiction; Europe and Asia may offer different pathways, extensions, or limitations. Global patent families are often constructed to maintain broader protection.
References
- US Patent 6,143,769, “Pharmaceutical Composition and Method of Treatment,” issued October 17, 2000.
- Hatch-Waxman Act, US Food and Drug Administration, 1984.
- World Intellectual Property Organization (WIPO) Patent Cooperation Treaty (PCT) filings.
- FDA’s Orange Book for patent and exclusivity data.
- Patent Landscape Reports by IP analysts, 2022.
Note: All information based on publicly available patent documentation and assumed details for illustration. Actual assignee names, filing data, and legal status should be verified through official patent databases.
More… ↓
⤷ Start Trial
|
